PERSPECTIVES

Latest post

The new Perspectives Magazine 2020 is here

The new issue of Oxurion Perspectives magazine is here. Read about last year's highlights and the ambitious times ahead.

back of the eye diseases, science community

Progressing development of therapies for retinal vascular disorders and diabetic eye disease

Patrik De Haes, M.D., CEO of Oxurion, and Thomas Clay, Chairman of the Board, review the year 2019.

back of the eye diseases, science community

Pravin Dugel, M.D.: “Biological signal for efficacy of THR-149”

“As an investigator of THR-149, I was encouraged to see the results from its clinical phase 1 trial", Pravin Dugel, M.D., says.

back of the eye diseases, science community

Phase 1 trial showed THR-149 is a highly potent plasma kallikrein inhibitor to treat DME

In 2019, Oxurion announced positive topline data for the compound THR-149, a highly potent plasma kallikrein inhibitor to treat diabetic macular edema (DME).

back of the eye diseases, science community

Arshad Khanani: “Initial data of phase 1 trial of THR-687 point to clinical efficacy”

Arshad Khanani, M.D., M.A. about the clinical phase 1 data of THR-687.

back of the eye diseases, science community

Positive phase 1 data indicate THR-687 could be an effective therapy for patients with DME

Oxurion kick-started 2020 with positive topline data from phase 1 clinical trial evaluating THR-687 for treatment of DME.

back of the eye diseases, science community

Professor Alan Stitt: Researching the AMD pathway

An interview with Alan Stitt about research in the AMD field.

science community

A strategic focus for Oxurion: researching and developing non-VEGF pathways

Jean Feyen, PhD., Chief Scientific Officer, and Andy De Deene, M.D., Global Head of Development, explain why Oxurion decided to focus on non-VEGF pathways.

back of the eye diseases, eye community

Oxurion NV Partners with Prevent Blindness to Educate Public on Diabetes-related Eye Disease

Both Oxurion and Prevent Blindness join forces during November to educate the public on risk factors, symptoms, treatment options, and financial assistance resources.

back of the eye diseases, science community

Research opportunities for treating age-related macular degeneration

Age-related macular degeneration (or AMD) is the leading cause of blindness. At Oxurion, we’re discovering new ways to treat both forms.

back of the eye diseases, eye community

3 reasons why we need to raise diabetic eye disease awareness

Diabetic eye diseases affect millions of people globally, and still there's a high unmet need in diagnosis and treatment. It's high time to get the message across to risk groups.

back of the eye diseases

9 striking facts about diabetic eye disease

In this post, we’ll share some striking facts and numbers about diabetes and diabetic eye disease.

back of the eye diseases, eye community

Sehnaz Karadeniz on tackling diabetes and related vision problems

Diabetic eye disease is currently one of the leading causes of preventable blindness in the working population worldwide. Early treatment and diagnosis is crucial for prevention.